EUVIMEDEUVIMED entdecken
Multizentrische Studie

Echocardiographic Phenotypic Differences Between Light-Chain and Transthyretin Cardiac Amyloid and Relation to Outcome

Izhan Hamza, Shriya Bavishi, Faysal Massad, Viral Desai, Christopher G Scott, Omar F AbouEzziddine, Angela Dispenzieri, Martha Grogan, Patricia A Pellikka

Journal of the American Society of Echocardiography · 2025-12 · 38 (12) · 1146-1158

DOI: 10.1016/j.echo.2025.08.017 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Society of Echocardiography, 2025-12. Verfasst von Izhan Hamza und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota; Department of Internal Medicine, University of Texas Medical Branch, Galves…. Hauptthemen laut MEDLINE: Echocardiography, Amyloid Neuropathies, Familial, Cardiomyopathies, Immunoglobulin Light-chain Amyloidosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Mayo Clinic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Light chain cardiac amyloidosis (AL-CA), wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), and hereditary-type transthyretin cardiac amyloidosis (ATTRv-CA) have distinct presentations, clinical courses, and prognosis. To identify differentiating echocardiographic features and their prognostic significance, we investigated a large cohort of patients with CA. METHODS: In this multisite cohort study, CA diagnosis was verified according to guidelines. Echocardiographic and clinical variables at the time of diagnosis were retrospectively compared. Previously validated staging for prognosis was applied, and Cox regression was utilized to identify additional echocardiographic variables independently associated with mortality. RESULTS: Of 1968 CA patients-age 67.5 ± 11.4 years, 1,456 (74%) male-1,128 (57.3%) had AL-CA, 624 (31.7%) had ATTRwt-CA, and 216 (11.0%) had ATTRv-CA. Patients with ATTRwt-CA were older, were more often male, and had more comorbidities. Patients with transthyretin cardiac amyloidosis (ATTR-CA) had greater left ventricular mass index and lower ejection fraction compared to those with AL-CA. Patients with ATTRwt-CA had larger left atrial volume index and higher proportion of aortic stenosis compared to other types. During median follow-up of 24 months, 953 patients died. During the first 3 years, patients with AL-CA had the highest mortality. Age and stroke volume index were independently associated with mortality in both AL-CA and ATTR-CA; sex and right ventricular s' were also independently associated with mortality for AL-CA. Adding stroke volume index to the staging prognostic model improved the C statistic by 0.03 (95% CI, 0.01-0.04) and 0.04 (95% CI, 0.02-0.05) for ATTR-CA and AL-CA, respectively. CONCLUSIONS: Among types of CA, distinct echocardiographic features were present at the time of diagnosis. Stroke volume index was independently associated with mortality and had incremental discriminatory power for mortality when added to staging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EchocardiographyAmyloid Neuropathies, FamilialCardiomyopathiesImmunoglobulin Light-chain AmyloidosisHumansMaleFemaleAgedRetrospective StudiesPhenotypePrognosisMiddle Aged

Stichwörter der Autor:innen

AmyloidCardiac amyloidosisCardiac imagingCardiomyopathyEchocardiography

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota; Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas.
  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
  • Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
  • Department of Hematology, Mayo Clinic, Rochester, Minnesota.
  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: pellikka.patricia@mayo.edu.

Förderung

  • Mayo Clinic

Zitieren

APA

Hamza, I., Bavishi, S., Massad, F., Desai, V., Scott, C. G., AbouEzziddine, O. F., Dispenzieri, A., Grogan, M., & Pellikka, P. A. (2025). Echocardiographic Phenotypic Differences Between Light-Chain and Transthyretin Cardiac Amyloid and Relation to Outcome. Journal of the American Society of Echocardiography, 38(12), 1146-1158. https://doi.org/10.1016/j.echo.2025.08.017

Vancouver

Hamza I, Bavishi S, Massad F, Desai V, Scott CG, AbouEzziddine OF, et al. Echocardiographic Phenotypic Differences Between Light-Chain and Transthyretin Cardiac Amyloid and Relation to Outcome. Journal of the American Society of Echocardiography. 2025;38(12):1146-1158. doi:10.1016/j.echo.2025.08.017

BibTeX
@article{Hamza2025,
  author = {Hamza, Izhan and Bavishi, Shriya and Massad, Faysal and Desai, Viral and Scott, Christopher G and AbouEzziddine, Omar F and Dispenzieri, Angela and Grogan, Martha and Pellikka, Patricia A},
  title = {Echocardiographic Phenotypic Differences Between Light-Chain and Transthyretin Cardiac Amyloid and Relation to Outcome},
  journal = {Journal of the American Society of Echocardiography},
  year = {2025},
  volume = {38},
  number = {12},
  pages = {1146--1158},
  doi = {10.1016/j.echo.2025.08.017}
}
Kostenlos starten →